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Millions of cardiac cells are lost immediately after an acute myocardial infarction (MI), thus critically endan-
gering the heart’s functional performance. Although a spec-
trum of spontaneous reparative reactions is activated to restore 
perfusion and contractility, these attempts are usually insuffi-
cient and also associated with adverse remodeling responses, 
which eventually lead to ventricular dysfunction and failure.
The underlying concept of cell therapy for cardiac repair is 
to provide the infarcted heart with exogenous supplements of 
regenerative elements to boost reparative vascularization and 
cardiomyogenesis. Transplantation of autologous stem cells 
currently represents the most popular and safe supply-side op-
tion. However, owing to their limited plasticity, single adult 
stem cell populations may not provide the desired multipurpose 
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Rationale: Optimization of cell therapy for cardiac repair may require the association of different cell populations 
with complementary activities.
Objective: Compare the reparative potential of saphenous vein–derived pericytes (SVPs) with that of cardiac stem 
cells (CSCs) in a model of myocardial infarction, and investigate whether combined cell transplantation provides 
further improvements.
Methods and Results: SVPs and CSCs were isolated from vein leftovers of coronary artery bypass graft surgery 
and discarded atrial specimens of transplanted hearts, respectively. Single or dual cell therapy (300 000 cells of each 
type per heart) was tested in infarcted SCID (severe combined immunodeficiency)-Beige mice. SVPs and CSCs alone 
improved cardiac contractility as assessed by echocardiography at 14 days post myocardial infarction. The effect 
was maintained, although attenuated at 42 days. At histological level, SVPs and CSCs similarly inhibited infarct 
size and interstitial fibrosis, SVPs were superior in inducing angiogenesis and CSCs in promoting cardiomyocyte 
proliferation and recruitment of endogenous stem cells. The combination of cells additively reduced the infarct 
size and promoted vascular proliferation and arteriogenesis, but did not surpass single therapies with regard to 
contractility indexes. SVPs and CSCs secrete similar amounts of hepatocyte growth factor, vascular endothelial 
growth factor, fibroblast growth factor, stem cell factor, and stromal cell–derived factor-1, whereas SVPs release 
higher quantities of angiopoietins and microRNA-132. Coculture of the 2 cell populations results in competitive as 
well as enhancing paracrine activities. In particular, the release of stromal cell–derived factor-1 was synergistically 
augmented along with downregulation of stromal cell–derived factor-1–degrading enzyme dipeptidyl peptidase 4.
Conclusions: Combinatory therapy with SVPs and CSCs may complementarily help the repair of infarcted 
hearts.  (Circ Res. 2015;116:e81-e94. DOI: 10.1161/CIRCRESAHA.115.306146.)
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solution. Apart from a recent study reporting the benefit of as-
sociative treatment with human mesenchymal stromal cells 
(MSCs) and human c-Kit+ cardiac stem cells (CSCs) in an im-
munosuppressed swine model of MI,1 combinatory cell thera-
py has received little attention. In particular, to the best of our 
knowledge, no previous study has investigated the advantage of 
dual therapy with cardiac and vascular stem/progenitor cells for 
harmonized repair of the infarcted heart.
CSCs have already been tested in first-in-human studies,2–5 
in spite of some persistent uncertainty around their capac-
ity to differentiate into mature cardiomyocytes and vascular 
cells in vivo.6–8 In the SCIPIO (Cardiac Stem Cell Infusion in 
Patients With Ischemic CardiOmyopathy) trial, cardiac cells 
were isolated from the right atrial appendage of patients un-
dergoing coronary artery bypass graft surgery, expanded and 
immunoselected to obtain c-Kit+ CSCs.2 In the CADUCEUS 
(CArdiosphere-Derived aUtologous stem CElls to reverse ven-
tricUlar dysfunction) study, cells were derived from percutane-
ous endomyocardial biopsy specimens and grown in primary 
culture where they develop multicellular clusters known as car-
diospheres.4,5 Cardiosphere-derived cells contain a mixture of 
stromal and mesenchymal cells, including c-Kit+ CSCs. Both 
studies did not raise safety concerns and showed encouraging 
results in terms of cardiac function improvement and scar size 
reduction.2–5 However, definitive clinical exploitation of c-Kit+ 
CSCs requires further verification and certification.9,10
Vascular pericytes are gaining momentum as a potential vas-
culogenic approach, but they still stand at the preclinical stage 
of experimentation.11–13 Noteworthy, pericytes are abundant in 
the heart, play important roles in vascular growth and stabiliza-
tion, and act as an interface between the coronary circulation 
and the cardiomyocyte compartment.14 However, harvesting 
pericytes from a patient’s heart entails an invasive procedure. 
To circumvent this problem, we have been focusing on dis-
carded saphenous vein remnants from coronary artery bypass 
graft surgery as a source of vascular pericytes. By recycling 
leftover products, we have developed a sustainable cell ther-
apy approach which was proven to help vascular and muscu-
lar repair in models of peripheral and myocardial ischemia.12,15 
Transplanted pericytes directly incorporate into the recipient 
vasculature and also stimulate reparative angiogenesis in a para-
crine manner. Interestingly, among the angiocrine factors se-
creted by pericytes, the microRNA-132 (miR-132) emerged as 
a multifunctional mechanism to promote angiogenesis and in-
hibit interstitial fibrosis. Moreover, pericytes indirectly induce 
endogenous cardiomyogenesis, by stimulating cardiomyocyte 
proliferation and attracting resident CSCs.12
This investigation aims to determine whether combined 
transplantation of saphenous vein–derived pericyte progeni-
tors (SVPs) and CSCs sourced from discarded surgical tis-
sue promotes the healing of mouse infarcted hearts better 
than single cell therapy. We show for the first time that the 
advantage of dual cell therapy derives from complementary 
actions on the recipient infarcted heart as well as transcrip-
tional and post-transcriptional interactions between the donor 
populations.
Methods
Expanded Methods are provided in the Online Data Supplement.
Human CSCs were isolated from discarded atrial specimens of hearts 
donated for transplantation.16 Human SVPs were immunosorted from 
vein leftovers of coronary artery bypass graft surgery patients.12,15 The 
main characteristics of donors are reported in Online Table. Cells were 
compared with regard to their antigenic phenotype and differentiation 
ability toward cardiovascular lineages. Interactions between cocultured 
SVPs and CSCs and paracrine effects on murine CSCs, cardiomyo-
cytes, and endothelial cells were investigated in vitro.
In in vivo studies,  severe combined immunodeficiency (SCID)-
Beige mice were intramyocardially injected with vehicle, SVPs, 
CSCs, or SVPs+CSCs (n=5–7 mice per group, total dosage of 300 000 
cells for each cell type), at the occasion of operative induction of MI. 
Cells were given at 3 different sites along the infarct border zone (final 
volume of 5 μL at each site) via micromanipulator-guided injection.12 
Cell dosage was decided on the basis of previous in vivo titration stud-
ies and consideration of the cell density/injection volume that can be 
accommodated in the mouse ventricular wall without producing myo-
cardial damage.12,17,18 Recovery of cardiac function was compared by 
echocardiography at 14 and 42 days from MI and cell therapy. Sham-
operated mice (n=6) were included as control. Additional studies were 
conducted to investigate the effect of cell therapy on proliferation 
(n=6 mice per each MI group and n=3 sham operated mice). To this 
purpose, mice were administered with intraperitoneal injections of 
5-ethynyl-2′-deoxyuridine (EdU) every 2 days.19
Results
Antigenic Phenotype and Differentiation Capacity
We first compared the antigenic profile of human SVPs and 
CSCs. As shown in Figure 1A, immunofluorescence analysis 
indicates that both cell types consistently express the pericyte 
markers NG2 (neural/glial antigen 2) and PDGF-Rβ (platelet-
derived growth factor receptor-beta) and are partly positive 
for the stemness marker SOX-2 ((sex determining region Y)-
box 2). However, c-Kit, NANOG (homeobox NANOG), and 
OCT-4 (octamer-binding transcription factor 4) were uniquely 
expressed by CSCs (with c-Kit expressed by 85.6±2.6% of 
CSCs, as assessed by flow cytometry (Online Figure IA). As 
shown in Figure 1B, flow-cytometry analysis indicates that 
both cell types abundantly express the mesenchymal markers 
CD105, CD44, and CD90, while being negative for endothe-
lial (CD31) and hematopoietic (CD45) antigens and for the 
surface glycoprotein CD34, which is typical of early hemato-
poietic and endothelial progenitor cells20 as well as of vascu-
lar wall-resident stem cells.21–24 It should be emphasized that 
SVPs derive from immunosorted CD34+ cells, but become 
CD34− during culture expansion.15
We next investigated the differentiation capacity toward 
cardiovascular lineages. By immunofluorescence microscopy, 
Nonstandard Abbreviations and Acronyms
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we confirmed the ability of CSCs to acquire markers of endo-
thelial (CD31), smooth muscle (α-smooth muscle actin), and 
cardiomyocyte lineages (myosin heavy chain), when cultured 
for 2 to 3 weeks in specific inductive media (Online Figure 
IB).16 After in vitro exposure to 2 distinct media that support 
CSC differentiation into cardiomyocytes,16,25 SVPs showed an 
upregulation of the constitutively expressed connexin-43 and 
became positive for α-sarcomeric actin (Online Figure IIA 
and IIB). In addition, both differentiation protocols induced 
Tbx5 and connexin-43 gene expression at mRNA level, as 
assessed by quantitative polymerase chain reaction analysis 
(Online Figure IIC and IID). However, SVPs failed to ex-
press other cardiomyocyte markers, such as cardiac troponin 
T (cTNNI3), myosin heavy chain (Myh7), Islet1, NKX2.5, 
and RyR2. Under induction of vascular differentiation, SVPs 
do not acquire vascular smooth muscle cell and endothelial 
cell markers (α-smooth muscle actin and CD31, respectively) 
as assessed by immunofluorescence microscopy (data not 
shown). This is consistent with our previous report showing 
maintenance of native pericyte characteristics in vitro as well 
as in vivo after implantation in the mouse infarcted myocar-
dium.12,15 Phenotypic and differentiative differences between 
CSCs and SVPs provide further rationale for direct face-to-
face confrontation of the 2 cell populations in in vivo studies.
Effect of Single and Dual Cell Therapy in a Model 
of MI
We next investigated the reparative capacity of single 
(300 000 cells per heart) or combined cell therapy (300 000 
CSCs+300 000 SVPs per heart) in immunodeficient SCID/
Beige mice that were subjected to acute MI by coronary artery 
ligature. Two follow-up studies were conducted to assess early 
(14 days) and late (42 days) outcomes (Figure 2).
Functional and Hemodynamic Outcomes
Echocardiography and intraventricular pressure data indicate 
that transplantation of single or combined cell populations en-
hances the spontaneous recovery from MI, with a remarkable 
improvement in ventricular function compared with vehicle at 
14 days post MI (Figure 3A and 3B). In particular, we found 
that SVPs improved a spectrum of contractility indexes, such 
as stroke volume, cardiac output, left ventricular (LV) ejec-
tion fraction, fractional shortening, and the rate of LV pres-
sure rise (dP/dt max), when compared with vehicle-receiving 
mice. CSCs significantly ameliorated LVEF. Comparing the 
2 cell populations, SVPs outperformed CSCs with regard to 
fractional shortening. Furthermore, the combined cell trans-
plantation did not show additive functional and hemodynamic 
improvements as compared with the single cell therapies. The 
beneficial effect of cell therapy persisted at the 42-day follow-
up assessment (Online Figure III).
Engraftment and In Vivo Differentiation of 
Transplanted Cells
The low survival rate of transplanted cells remains a major limi-
tation of cell therapy.26–28 Moreover, it is not known whether 
donor cells resist differently within the ischemic myocardium 
when injected alone or in combination. Therefore, we verified 
the presence of human cells in the mouse heart using 2 dif-
ferent techniques: (1) by prelabeling SVPs and CSCs before 
Figure 1. Cell characterization. A, Epifluorescence microscopy 
analysis of cardiac stem cells (CSCs) and saphenous vein–derived 
pericytes (SVPs) for the expression of the pericyte markers NG2 
(neural/glial antigen 2) and PDGF-Rβ (platelet-derived growth factor 
receptor-beta), the stem cell factor receptor c-Kit and the stemness 
markers NANOG (homeobox NANOG), OCT-4 (octamer-binding 
transcription factor 4) and SOX-2 ((sex determining region Y)-box 
2). Nuclei are shown by the blue fluorescence of 4′,6-diamidino-2-
phenylindole. Scale bar, 50 μm. B, Flow-cytometry analysis of cultured 
CSCs and SVPs. Isotype control IgG staining profiles are shown by the 
red border line histograms, whereas specific antibody staining profiles 
are shown by full green histograms. For each cell type, histograms 
representative of 1 of the 7 cell lines analyzed have been shown. The 
percentages of markers expression relative to all the cell lines (n=7 
CSCs; n=7 SVPs) are reported on the graphs as mean±SEM.
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transplantation with the long-term cell trackers VyBrant DiL 
and DiO (from Life Technologies), respectively and (2) by 
fluorescent immunostaining with an antibody that selectively 
recognizes human nuclear antigens. We found that, at 14 days 
post injection, clusters of SVPs were present in all the sections 
analyzed (5–10 for each heart cut at different levels along the 
infarcted LV) both within the infarct zone and in the region 
bordering the infarction (Online Figure IVA, IVC, IVD). This 
result is consistent with our previous findings documenting the 
peculiar resilience of SVPs to ischemic stress.12,29 Clusters of 
human CSCs could be also detected in the recipient heart, al-
though they were not present in all the samples and were less 
abundant than SVPs (Online Figure IVB, IVE, and IVF). In 
hearts receiving combined cell therapy (in which cells were la-
beled with DiL and DiO), we did not observe increased engraft-
ment or spatial connections between SVPs and CSCs.
Importantly, neither SVPs nor CSCs were positive for the 
endothelial murine marker isolectin-B4, suggesting the lack 
Figure 3. Effect of single or combined 
cell therapy on echocardiographic and 
hemodynamic parameters 14 days after 
myocardial infarction (MI). Data are presented 
as mean±SEM (n=6–7 mice per group). #P<0.05, 
##P<0.01, ###P<0.001, and ####P<0.0001 vs Sham; 
*P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001 
vs vehicle; $P<0.05 vs saphenous vein–derived 
Pericytes (SVP). CO indicates cardiac output; 
FS, fractional shortening; LVAWd, left ventricular 
anterior wall at diastole; LVAWs, left ventricular 
anterior wall at systole; LVEDP, left ventricular 
end-diastolic pressure; LVEDV, left ventricular end-
diastolic volume; LVEF, left ventricular ejection 
fraction; LVESP, left ventricular end-systolic 
pressure; LVESV, left ventricular end-systolic 
volume; LVIDd, left ventricular internal diameter at 
diastole; LVIDs, left ventricular internal diameter at 
systole; and SV, stroke volume. 
Figure 2. Schematic drawing of the experimental 
plan for the in vivo studies performed in a mouse 
model of myocardial infarction (MI). SCID (severe 
combined immunodeficiency)/Beige-immunodeficient 
mice were intramyocardially injected with saphenous 
vein–derived pericytes (SVPs; 300 000 cells per heart), 
cardiac stem cells (CSCs; 300 000 cells per heart), 
SVPs+CSCs (300 000 cells of each type per heart) 
or vehicle at the occasion of MI induction, and 
euthanized 14 or 42 days thereafter. Sham-operated 
mice were included as control. For the short-term 
follow-up study, a group of animals were injected 
with 5-ethynyl-2′-deoxyuridine (EdU) every 2 days, for 
proliferation studies.
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of an in vivo differentiation into endothelial cells (Online 
Figure IVC and IVE). In addition, rare isolated SVPs express 
the endothelial human antigen CD34 (Online Figure IVD) and 
a few human CSCs, but not SVPs, express the cardiomyocyte 
marker α-sarcomeric actin, suggesting an in situ differen-
tiation of the former cells into cardiomyocyte-precursor cells 
(Online Figure IVF).
At 42 days post injection, no CSCs or SVPs could be de-
tected in the recipient hearts. In all the analyses performed, 
we included a human myocardial sample as a positive control 
to verify the labeling efficiency of the antihuman nuclear an-
tibody (labeling efficiency, 96%; Online Figure V). Moreover, 
we verified that the cell trackers are taken up by >90% of cells 
(data not shown). Finally, we performed a spectral dye separa-
tion to validate the specificity of the antihuman nuclei anti-
body immunofluorescence signal (Online Figure VI).
Infarct Size, Interstitial Fibrosis, and Ventricular/
Cardiomyocyte Remodeling
We next assessed the effect of cell therapy on infarct size and 
interstitial fibrosis in the spared myocardium. Results indicate 
a trend toward infarct reduction by single cell therapy as com-
pared with vehicle (P>0.2). However, only the group given 
dual cell therapy manifested a significant decrease in the vol-
ume of LV occupied by the scar (P<0.05 versus vehicle at 14 
days post injection; Figure 4A). At 42 days, linear measure-
ment of the scar confirmed the beneficial effect of dual cell 
therapy, although the difference versus single cell therapy did 
not reach statistical significance (Online Figure VII). In addi-
tion, single and dual cell therapies were equivalent in attenuat-
ing interstitial fibrosis (P<0.0001; Figure 4B).
In order to evaluate the effect of cell therapy on postinfarct 
remodeling, we measured the weight of LV after dissecting it 
from the other parts of the heart (Online Figure VIII). As shown 
in Figure 4C, LV weight was increased in the MI group given 
vehicle (P<0.05 versus sham operated), with this effect being 
attenuated by cell therapy. After an acute MI, myocyte volume 
is increased as an attempt to compensate the loss of myocardial 
mass. Therefore, we next examined the effect of cell therapy on 
myocyte cross-sectional area in both the remote and the peri-
infarct myocardium. As expected, vehicle-receiving hearts 
were characterized by myocytes of greater dimensions and a 
reduction in the cardiomyocyte nuclear density as compared 
with sham-operated mice (P<0.001 for both comparisons; 
Figure 4D). These remodeling responses were attenuated in 
hearts that received CSC or SVP+CSC cell therapy.
Myocardial Repair
We next analyzed the effect of cell therapy on myocyte pro-
liferation and apoptosis in the infarct border zone (Figure 5A 
and 5B). ANOVA detected an effect of cell therapy on both 
the histological outcomes (P<0.01). In multiple comparison 
analysis, CSCs surpassed SVPs with respect to cardiomyocyte 
proliferation, whereas combined treatment did not further im-
prove the outcomes as compared with the best single therapy.
Importantly, cell therapy also exerted a supportive effect on 
the abundance of endogenous c-Kit+ cells in the peri-infarct 
zone (ANOVA, P<0.0001; Figure 5C). About the classes of 
cells involved in the process, we observed an enhancement 
of the more primitive stem cells and progenitor cells (c-Kit+ 
αSA−), but not of myocyte precursors (c-Kit+ αSA+). In mul-
tiple comparison analyses, CSCs resulted to be more effective 
than SVPs in enhancing the number of primitive stem cells 
and progenitor cells. The combined cell transplantation did 
not surpass the effect of the best single treatment.
Vascular Repair
Immunohistochemistry analysis of peri-infarct microvasculature 
at 14 days post injection showed a higher density of capillar-
ies and arterioles in cell-transplanted groups with respect to the 
vehicle group (ANOVA, P<0.05; Figure 5D and 5E). Multiple 
comparison analysis revealed that SVPs surpassed CSCs with 
regard to the microvascular density outcome. At 42 days, we 
observed that higher capillary density persisted in SVP- and 
SVP+CSC-treated hearts (Figure 5F). In addition, dual cell ther-
apy promoted the growth of large arteriole density (Figure 5F). 
A superior proangiogenic capacity of SVPs versus CSCs was 
confirmed in an in vitro Matrigel assay (Online Figure IX).
Cumulative Cell Proliferation
To further investigate how the different cell therapies promote 
the processes of cardiomyogenesis and vasculogenesis, we 
administered a group of mice with the nucleoside analogue 
EdU.19 EdU labeling in vivo provides an accumulative measure 
of new myocyte and vascular cell formation during the 2-week 
time post MI, whereas the Ki67+ myocytes represent the ones 
that were still or had recently been in the cell cycle just be-
fore euthanization. Interestingly, results confirm that CSCs are 
better than SVPs in stimulating cardiomyocyte proliferation 
(P<0.01; Figure 6A and 6B). The combined transplantation 
of SVPs and CSCs did not show additive improvements over 
CSCs alone. These data, together with the finding of higher 
cardiomyocyte density and reduced cardiomyocyte cross-
sectional area, suggest that CSC therapy stimulates myocyte 
proliferation in the infarcted heart.
About the process of vascularization, results confirmed that 
SVPs outperform CSCs in stimulating the proliferation of 
capillary endothelial cells (P<0.05 versus vehicle and CSCs; 
Figure 6C and 6D). In agreement with data showing an ad-
ditive effect of dual therapy on arteriogenesis, we found that 
transplantation of SVPs and CSCs increases the density of 
EdU+ vascular smooth muscle cells within arteriolar vessels 
(P<0.05; Figure 6C–6E).
Altogether, these data indicate that SVPs and CSCs exert 
prevalent actions on angiogenesis and myogenesis, respec-
tively. Furthermore, dual cell therapy exerts additional benefit 
on the infarct size and arteriogenesis, but was similar to single 
cell therapy with regard to other outcomes. In the light of 
these differences, we performed additional studies in vitro to 
assess reciprocal, either positive or contrasting, interferences 
between the 2 cell populations.
Reciprocal Influence on Proliferation, Viability and 
Paracrine Activity
Although an interaction between transplanted and resident 
stem cells has been proposed,15,30 little is known about the re-
ciprocal influence of different donor cells. Therefore, we next 
performed in vitro coculture studies to determine whether 
SVPs and CSCs may affect each other with regard to several 
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Figure 4. Morphometric evaluation of the left ventricle in mice 14 days post myocardial infarction (MI) and cell therapy.  
A, Evaluation of infarct size. (i) Representative images of Azan Mallory staining in ventricular sections; collagen fibers are stained in blue 
(×12.5 magnification). (ii) Bar graphs summarize quantitative data of the percentage of the left ventricle occupied by the scar.  
B, Evaluation of interstitial fibrosis. (i) Representative images of Azan Mallory staining in ventricular sections (×200 magnification). (ii) Bar 
graphs summarize quantitative data of the percentage of the interstitial fibrotic area in the noninfarcted left ventricle. C, Left ventricular 
(LV) mass measurement after fixation of the whole heart with 4% paraformaldehyde and the following separation of the left ventricle from 
the atria and the right ventricle. D, Evaluation of cardiomyocyte hypertrophy. (i) Representative confocal images of wheat germ agglutinin 
(WGA; green), α-sarcomeric actin (red) and 4′,6-diamidino-2-phenylindole (DAPI; blue) in sham mice and in the peri-infarct (border zone) 
and remote myocardium (remote zone) of MI-mice. (ii–v) Histograms summarize quantitative data of cardiomyocyte cross-sectional 
area (ii and iii) and nuclear density (iv and v) in the border and remote myocardium. Data are presented as mean±SEM (n=3–4 sham, 
n=5–7 mice per each MI group). #P<0.05, ##P<0.01, and ###P<0.001 vs Sham; *P<0.05, **P<0.01, and ***P<0.001 vs vehicle; §P<0.05 vs 
saphenous vein–derived pericytes (SVP). CSC indicates cardiac stem cell.
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Figure 5. Effect of single or combined cell therapy on vascularization, cardiomyocyte proliferation/viability, and endogenous 
cardiac stem cell abundance. A and B, Cardiomyocytes in the peri-infarcted ventricles 14 days post myocardial infarction (MI). Confocal 
images of cardiomyocytes: Ai, the red fluorescence of Ki67 indicates proliferating cardiomyocytes; (Bi) the green fluorescence of terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) recognizes apoptotic cardiomyocytes. Cardiomyocyte cytoplasm is labeled 
by α-sarcomeric actin, represented in white. Nuclei are recognized by the blue fluorescence of 4′,6-diamidino-2-phenylindole (DAPI). 
Histograms summarize quantitative data of cardiomyocytes proliferation (Aii) and apoptosis (Bii) in the infarct border zone. C, (Continued)
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functional properties. To distinguish 1 cell type from the other 
in a coculture system, SVPs were labeled with the cell track-
er DiL. Uptake of DiL was confirmed in 95% of treated cells 
(Figure 7A).
We first compared the 2 cell populations with respect to pro-
liferation rate and starvation-induced apoptosis, in single culture 
or coculture at a 1:1 ratio, which is the same proportion used 
for combined cell therapy in vivo. In both conditions, CSCs 
showed a higher incorporation rate of EdU (P<0.01 versus 
SVPs; Figure 7B) and a higher propensity to undergo starvation-
induced apoptosis (P<0.05 versus SVPs; Figure 7C). Moreover, 
we verified the reciprocal effect on viability in a coculture cham-
ber system where the 2 cell populations were exposed to the 
same starvation medium (serum-free EGM-2 [endothelial cell 
Figure 6. Cardiomyogenesis and vasculogenesis in the left ventricle 14 days post myocardial infarction (MI). and cell therapy. A, 
Representative confocal image of an 5-ethynyl-2′-deoxyuridine (EdU)+ cardiomyocyte in the peri-infarct region. Nuclear EdU is depicted 
in white, whereas cardiomyocyte cytoplasm is labeled by α-sarcomeric actin (α-SA), in red fluorescence. B, Bar graphs show quantitative 
data of EdU+ cardiomyocyte nuclei in the peri-infarct myocardium. C, Representative confocal images of capillaries and small and large 
arterioles in the peri-infarct myocardium. Isolectin-B4 (IB4) is shown in green, α-smooth muscle actin (α-SMA) in red, whereas nuclear 
EdU is shown in red or in green. 4′,6-Diamidino-2-phenylindole (DAPI) is represented in blue. Cells positive for EdU are identified by 
white arrows. D to E, Bar graphs show the density of EdU+ capillaries (D) and small (<20 μm in diameter) and large (>20 μm in diameter) 
arterioles (E) in the peri-infarct myocardium. Data are presented as mean±SEM (n=3 sham, n=6 mice per each MI group). #P<0.05, 
##P<0.01, and ###P<0.001 vs. Sham; *P<0.05 and **P<0.01 vs vehicle; §P<0.05 vs saphenous vein–derived pericytes (SVP). CSC indicates 
cardiac stem cell.
Figure 5 Continued. Endogenous primitive cardiac stem cells in the peri-infarcted ventricle, 14 days post MI. Upper, Confocal images of 
(i) cardiac stem/progenitor cell (c-Kit+ αSA− Tryptase−) and cardiomyocyte precursor cell (c-Kit+ αSA+ Tryptase−); (ii) cardiac stem/progenitor 
cell (c-Kit+ αSA− Tryptase−); (iii) cardiac mastocytes (c-Kit+ Tryptase+). c-Kit is stained in red, mast cell tryptase in green, α-sarcomeric 
actin in white, and nuclei in blue (DAPI). Bottom, Histograms summarize quantitative data of the density of (iv) total cKit-positive cardiac 
primitive cells, (v) stem and progenitor cells, and (vi) cardiomyocyte precursors in the infarct border zone of left ventricles. D to F, 
Angiogenesis in peri-infarcted ventricle. D, Representative epifluorescence image of isolectin B4 (IB4; green), α-smooth muscle actin 
(α-SMA; red) and DAPI (blue). Bar graphs show the density of capillaries and small (<20 μm in diameter) and large (>20 μm in diameter) 
arterioles, 14 days (E) and 42 days (F) post MI. Data are presented as mean±SEM (n=4 sham, n=5–7 mice per each MI group). #P<0.05, 
##P<0.01, and ###P<0.001 vs Sham; *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001 vs vehicle; §P<0.05 vs saphenous vein–derived 
pericytes (SVP). CSC indicates cardiac stem cell.
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Figure 7. In vitro interaction between cardiac stem cells (CSCs) and saphenous vein–derived pericytes (SVPs) and cell secretome. For 
coculture experiments, SVPs have been labeled with the cell tracker VyBrant DiL (from Life Technologies). A, A representative image of labeled 
SVPs. The efficiency of labeling is 95%. B, Cell proliferation. Histograms show the percentage of 5-ethynyl-2′-deoxyuridine (EdU)+ CSCs and SVPs 
in single or combined-culture (seeding cells following a 1:1 ratio), after a 20-hour long incubation in medium supplemented with EdU. C and D, Cell 
apoptosis. Histograms show the percentage of apoptotic cells, in single or combined culture, after a starvation of 48 hours in EGM-2 (endothelial cell 
growth medium-2) serum-free medium. Cells in coculture were in contact (C) or separated by a semipermeable membrane (D). Data are presented 
as mean±SEM (n=3 per group). *P<0.05, **P<0.01 vs saphenous vein–derived pericytes (SVPs); #P<0.05 vs CSCs in single culture. E, Secretome of 
SVPs, CSCs, and cocultures of SVPs+CSCs, in normoxia (20% oxygen) and hypoxia (2%). (i–viii) Histograms show the amount of secreted factors 
normalized for the volume of the collected supernatant, cell number, and time of incubation. (vii) miR-132 released in cell supernatant. For each group 
of cells, fold change of the normoxic culture is reported. Data are presented as mean±SEM (n=3 per group). *P<0.05, **P<0.01, and ***P<0.001. 
F, Transcriptional changes of angiopoietins (ANGs) and stromal cell–derived factor-1α (SDF-1α) in CSCs and SVPs (both n=3) exposed for 6 hours to 
each other conditioned medium. Histograms show the n-fold change with respect to untreated cells. Data are presented as mean±SEM. *P<0.05 and 
***P<0.001 vs untreated cells. G, Dipeptidyl peptidase 4 (DPP-4) mRNA expressional levels in SVPs and CSCs assessed by quantitative polymerase 
chain reaction analysis. Histograms show the n-fold change with respect to CSCs. Data are presented as mean±SEM (n=4 CSCs, 5 SVPs). *P<0.05 
vs CSCs. H, Transcriptional changes of DPP-4 in CSCs (n=4) exposed for 6 hours to SVP conditioned medium. Histograms show the n-fold change 
with respect to untreated cells. Data are presented as mean±SEM. **P<0.01 vs untreated cells. I, Histograms show the amount of secreted DPP-4 
in supernatants of SVPs, CSCs, and cocultures of SVPs+CSCs, in hypoxia. Data are normalized for the volume of the collected supernatant, cell  
number, and time of incubation. Data are presented as mean±SEM (n=4 per group). *P<0.05 vs SVPs, §P<0.05 vs CSCs. bFGF indicates basic 
fibroblast growth factor; HGF, hepatocyte growth factor; SCF, stem cell factor; and VEGF, vascular endothelial growth factor.
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growth medium-2 from Lonza]), but kept separated by a semi-
permeable membrane to avoid mutual contacts. As shown in 
Figure 7D, the abundance of terminal deoxynucleotidyl transfer-
ase dUTP nick end labeling–positive CSCs was higher than that 
of SVPs, either when cells were kept alone or together (P<0.01 
for both comparisons), thus confirming the results of the mixed 
coculture experiment described above. Noteworthy, cell coincu-
bation halved the fraction of terminal deoxynucleotidyl trans-
ferase dUTP nick end labeling+ CSCs (P<0.05 versus single 
culture), thus suggesting that SVPs secrete factors that increase 
CSC viability. Altogether these in vitro data indicate that the 
mixture of different stem cells does not alter their proliferation 
rate and resistance to starvation, with the latter property being 
eventually improved if cells are not in contact.
Transplanted cells secrete combinations of trophic factors 
that modulate the molecular composition of the ischemic en-
vironment to evoke healing responses.31,32 However, to the best 
of our knowledge, it remains unknown whether different stem 
cell types in combination may influence each other’s secre-
tome. To investigate these paracrine interactions, we measured 
growth factors and cytokines secreted by SVPs and CSCs in 
single culture or coculture under normoxic or hypoxic con-
ditions. The secretory capacity was calculated by normaliz-
ing the amount of a given secreted factor by the cell number, 
which was assessed at the end of the collection period.
We found that SVPs and CSCs release similar levels of he-
patocyte growth factor and stem cell factor, with no substantial 
changes in normoxia versus hypoxia or monoculture versus 
coculture (Figure 7Ei and 7Eii). Noteworthy, SVPs secrete the 
proangiogenic factors angiopoietin 1 (ANG1) and 2 (ANG2) at 
higher concentrations than CSCs (P<0.05 and 0.01, respectively; 
Figure 7Eiii and 7Eiv). A similar trend was observed with basic 
fibroblast growth factor although the difference did not reach 
statistical significance (Figure 7Ev). Interestingly, the secretion 
of angiopoietins and basic fibroblast growth factor by cells in 
coculture was lower than the average of the 2 cell preparations, 
thus suggesting a negative reciprocal interference. Moreover, 
hypoxia induced an increase in the secretion of vascular endo-
thelial growth factor by CSCs, but this effect was not observed 
in the SVP-CSC coculture (Figure 7Evi). Proangiogenic growth 
factors induce miR-132 expression in vascular cells via activa-
tion of the transcription factor cAMP response element-binding 
protein.33 Furthermore, we have previously demonstrated that 
SVPs abundantly express and release miR-132 and that secret-
ed miR-132 is in part responsible for the SVP ability to induce 
reparative angiogenesis and reduce infarct size after transplan-
tation in the mouse heart.12 Therefore, we next investigated the 
reciprocal interference of SVPs and CSCs on miR-132 secre-
tion under normoxia or hypoxia. Interestingly, we found an op-
posite behavior of the 2 cell types: in fact, hypoxia increases 
the miR-132 levels in SVP conditioned medium (P<0.05 versus 
normoxia) as reported by us previously,12 but reduces miR-132 
in CSC conditioned medium (P<0.01 versus normoxia; Figure 
7Evii). However, we observed an additive effect of the cell 
coculture on the secretion of stromal cell–derived factor 1α 
(SDF-1α) under normoxia (ANOVA, P<0.05; Figure 7Eviii). 
This phenomenon was more evident under hypoxia (ANOVA, 
P<0.01), being the SDF-1α secretion by cocultured cells greater 
than the sum of individual cell culture systems (Figure 7Eviii). 
Altogether, these data newly indicate a complex interactive be-
havior at the level of secretome, which may result in attenuated 
secretion of vascular endothelial growth factor, ANG1, ANG2, 
basic fibroblast growth factor, and miR-132 in comparison with 
the prominent cell producer, but synergic release of SDF-1α.
To determine whether these phenomena are transcription-
ally modulated, we performed quantitative polymerase chain 
reaction analyses of angiopoietins and SDF-1 mRNA levels in 
SVPs and CSCs before and after 6-hour exposure to each oth-
er’s conditioned medium. As shown in Figure 7F, conditioned 
media reduced the expression of ANG2 in both the cell types 
(P<0.001 for SVPs, P<0.05 for CSCs versus the respective cell 
control exposed to unconditioned medium), whereas ANG1 
remained unaltered. In addition, CSCs exposed to SVP condi-
tioned medium showed reduced SDF-1α mRNA levels (P<0.05 
versus CSCs exposed to unconditioned medium). These data 
newly show a transcriptional interference with respect to ANG2 
and SDF-1. However, while ANG2 expression was consistently 
reduced at mRNA and protein level, the increase in SDF-1α 
content in coculture media cannot be attributed to the induction 
of gene transcription, but rather to an increase in secretion rate.
Chemokine availability in the extracellular compartment is 
also dictated by the activity of degrading enzymes. Dipeptidyl 
peptidase-4 (DPP-4), also known as adenosine deaminase 
complexing protein 2 or CD26 (EC 3.4.14.5), cleaves a spec-
trum of proline- or alanine-containing chemokines, includ-
ing SDF-1α. Importantly, increased SDF-1α availability has 
been proposed to mediate the cardioprotective and proangio-
genic activity of DPP-4 inhibitors in MI models.34 As shown 
in Figure 7G, quantitative polymerase chain reaction analy-
sis shows that DPP-4 is more expressed by CSCs than SVPs 
(P<0.05). Furthermore, DPP-4 is downregulated in CSCs ex-
posed to SVP conditioned medium (P<0.01; Figure 7H). In 
keeping with transcriptional results, ELISA of conditioned 
media confirmed higher DPP-4 secretion by CSCs (P<0.05 
versus SVPs), which is attenuated when CSCs are cocultured 
with SVPs (P<0.05 versus CSCs alone; Figure 7I).
Functional Impact of SVP and CPC Secretomes on 
Endothelial Cells, Cardiomyocytes, and CSCs
To investigate the effect of secretome on specific target cells, 
we first tested the proangiogenic capacity of SVPs, CSCs, and 
their coculture in a Matrigel endothelial network assay. As 
shown in Figure 8A, ANOVA detected a positive effect of con-
ditioned media on network formation by human umbilical vein 
endothelial cells (P<0.05 versus unconditioned medium), but 
no additive effect was observed with SVP-CSC combination as 
compared with single conditioned media. Instead, only SVP and 
SVP+CSC conditioned media are able to stimulate the prolifera-
tion of human umbilical vein endothelial cells (P<0.05 versus 
EGM-2), with this effect being refused to CSCs (Figure 8B).
We next investigated the protective effect of SVP and CSC 
secreted factors against apoptosis after simulated ischemia/re-
oxygenation in isolated adult rat cardiomyocytes. The purity of 
the cell preparation was assessed by staining with α-sarcomeric 
actinin antibody (Figure 8C). As shown in Figure 8D, the sim-
ulated ischemia/reoxygenation protocol effectively induces 
cardiomyocyte apoptosis compared with normoxia. We found 
that the secretome of each cell population is able to protect 
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rat cardiomyocytes from apoptosis (P<0.001 versus uncondi-
tioned medium for both comparisons), with no additive effect 
when using the coculture conditioned media (Figure 8E).
Finally, we verified the effects of conditioned media on 
murine CSCs. Figure 8F shows a typical immunofluorescence 
microscopy image of Sca-1+ cells isolated from the mouse 
heart.35 As illustrated in Figure 8G and 8H, conditioned media 
did not affect Sca-1+ cell proliferation or apoptosis. However, 
they markedly stimulated the migration of murine Sca-1+ cells 
in a Boyden chamber assay (P<0.01 for both comparisons), 
Figure 8. Functional impact of the secretome(s) on endothelial cells, cardiomyocytes, and cardiac stem cells. A, Angiogenesis 
assay. Matrigel assay: Representative phase-contrast optical images of human umbilical vein endothelial cells (HUVECs) forming tubular 
networks when cultured for 6 hours on Matrigel substrate, with EGM-2 (endothelial cell growth medium-2) media conditioned by saphenous 
vein–derived pericytes (SVPs), cardiac stem cells (CSCs), or SVPs+CSCs or unconditioned medium (UCM; magnification ×50). Histograms 
summarize quantitative data of the tubes length per field. n=5 per each group. B, Effect of cell secretome on HUVECs proliferation. Histograms 
summarize quantitative data of cell proliferation (measured as incorporation of BrdU [5-bromo-2'-deoxyuridine]) in HUVECs cultured in 
medium conditioned by SVPs, CSCs, or SVPs+CSCs or UCM for 40 hours, in the presence of BrdU. Data are fold changes of UCM. n=3 per 
group. C to E, Simulated ischemia reoxygenation (SI/RO) injury on isolated adult rat cardiomyocytes. C, Confocal image of cardiomyocytes 
in culture. Cardiomyocytes cytoplasm is labeled by α-sarcomeric actinin stained in red, whereas nuclei are shown in blue (4′,6-diamidino-2-
phenylindole [DAPI]). D, Histograms summarize quantitative data of apoptosis (measured as caspase 3/7 activity) in cardiomyocytes after 
the SI/RO compared with control cells cultured in basal conditions. E, Histograms summarize quantitative data of apoptosis (measured as 
caspase 3/7 activity) in cardiomyocytes subjected to SI/RO and cultured in medium conditioned by SVPs, CSCs, or SVPs+CSCs or UCM. n=3 
for each group. F to I, Effects of cell secretome on mouse Sca-1+ cardiac stem cells. F, Epifluorescence image of Sca-1+ cardiac stem cells in 
culture. Sca-1 on cell surface is stained in red, whereas nuclei (DAPI) are shown in blue. G, Proliferation. Histograms summarize quantitative 
data of cell proliferation (measured as incorporation of BrdU) in Sca-1+ cells cultured in medium conditioned by SVPs, CSCs, or SVPs+CSCs 
or UCM for 16 hours, in the presence of BrdU. Data are fold change of UCM. H, Apoptosis. Histograms summarize quantitative data of cell 
apoptosis (measured as caspase 3/7 activity) in Sca-1+ cells cultured in medium conditioned by SVPs, CSCs, or SVPs+CSCs or UCM for 
48 hours, in serum-free medium; data are fold change of UCM. n=3 for each group. I, Cell migration. Histograms show the percentage of 
Sca-1+ cells migrated toward SVPs, CSCs, or SVPs+CSCs conditioned medium or UCM, during a period of 8 hours. n=3 per group. Data are 
presented as mean±SEM. *P<0.05, **P<0.01, and ***P<0.001 vs UCM; §P<0.05 and §§P<0.01 vs SVPs.
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with no additive effect being observed after stimulation with 
the coculture conditioned media (Figure 8I).
Discussion
This study provides new important insights into the optimiza-
tion of cell therapy for cardiac repair using populations with 
complementary healing properties. We show that, by combining 
the capacities of human CSCs to promote cardiomyogenesis, 
via recruitment of endogenous stem cells and induction of car-
diomyocyte reentry into the cell cycle, and of human SVPs to 
boost vascularization, it becomes possible to obtain additive re-
duction of the scar size in a murine model of MI. However, dual 
cell therapy did not surpass the best-performing cell population 
with regard to other outcome measures, including contractility 
and pressure indexes, myocyte remodeling, and interstitial fi-
brosis. In addition, results newly show a previously unforeseen 
paracrine interaction between the 2 cell populations.
Feasibility and efficacy of CSCs have been already tested 
in clinical trials.2–5 Nevertheless, there are multiple challenges 
to the use of autologous CSCs, including among the others the 
need of a cardiac biopsy. We have now developed a clinical-
grade version of the SVP expansion protocol from discarded 
human veins for use at the GMP facilities of NHS Blood and 
Transplant, which is a Special Health Authority with responsi-
bility for managing the supply of blood, organs, and tissues in 
the UK. Therefore, SVPs represent a practical alternative as well 
as a convenient complement to CSCs for cardiac cell therapy.
There are few antecedent studies investigating combinatory 
cell therapy approaches. A recent report by Williams et al1 com-
bining human CSCs and bone marrow MSCs in a swine model 
of MI showed that each cell therapy reduces MI size relative 
to placebo, with the MI size reduction being 2-fold greater in 
combination versus either cell therapy alone. These results are 
similar to ours; however, in Williams’ report there was a substan-
tial improvement in LV chamber compliance and contractility by 
dual cell therapy, whereas we could not observe additional bene-
fit over single therapy. It should be noted that in Williams’s study 
the engraftment of CSCs and MSCs in the combination group 
was 7-fold greater than in either cell group administered alone,1 
whereas we did not observe such a remarkable effect. Besides 
the different animal models used (pharmacologically immu-
nosuppressed pigs undergoing ischemia/reperfusion versus 
immunodeficient mice undergoing permanent coronary artery 
occlusion), the 2 studies also differ in terms of time points for 
cell therapy injection after MI induction: whereas in Williams’ 
study cells were intramyocardially injected at 14 days post MI, 
we performed cell therapy at the occasion of coronary artery oc-
clusion. The late application might account for a better cell en-
graftment and contractility improvement. Additional reasons for 
the discrepancy in functional outcomes remain to be elucidated.
Direct contact and paracrine signaling between cells induce 
functional changes and may also influence the susceptibility to a 
variety of stressors. In addition, competitive interaction between 
stem cells within their native niches reportedly results in survival 
of the fittest stem cells and death of the more susceptible cells.36 
Expanding these concepts to cell therapy, the outcome of dual 
cell delivery may depend on the balance between cooperative and 
competitive interactions. We ruled out any negative effect of pool-
ing SVPs and CSCs before intramyocardial delivery. In addition, 
we observed improved cell viability when SVPs and CSCs were 
cultured in the same in vitro system, but kept separated by a filter. 
Noteworthy, when comparing the secretome of single and dual 
cell products, we observed important changes at transcriptional 
and post-transcriptional level. In particular, SVPs secrete larger 
amounts of angiogenic factors, such as angiopoietins, basic fi-
broblast growth factor, and miR-132, as compared with CSCs. 
However, angiocrine secretion per cell unit was reduced below 
the average of each cell population when SVPs and CSCs were 
cultured together, thus suggesting an inhibitory effect. In both 
cell populations, this inhibition is likely to occur at transcriptional 
level for ANG2 but not for ANG1, as indicated by the reduction of 
ANG2 mRNA levels when cells are exposed to media conditioned 
by the other cell type. However, analysis of the secretome indi-
cates that SDF-1α release is remarkably increased in the coculture 
system. We verified that in both cell populations this modulation 
occurs at post-transcriptional level and may involve a reduction in 
SDF-1αdegradation by DDP4. Previous studies have shown that 
SDF-1α plays a key role in recruiting bone marrow–derived stem 
cells to the sites of vascular and myocardial injury.37,38 Furthermore, 
transplantation of cardiac fibroblasts, MSCs, or skeletal myoblasts 
genetically engineered to express high constitutive levels of SDF-
1αreportedly reduces cardiomyocyte death, increases vascular 
density, and improves cardiac function in preclinical models of 
myocardial ischemia.37,39,40 Likewise, early intravenous infusion 
of hypoxia-preconditioned, cardiosphere-derived c-Kit+ Lin− cells 
induces general cardiac benefit in a murine model of MI.41 This 
effect was attributed to an activation of the SDF-1α/CXCR4 axis, 
as both cell engraftment and functional improvements from cell 
therapy were inhibited by preincubation of c-Kit+ Lin− cells with 
MD-3100, a CXCR4 antagonist.41 There is also initial evidence 
that prolongation of SDF-1α expression at the time of acute MI 
by infusion of SDF-1α–engineered MSCs leads to the recruitment 
of small-size, myosin, and connexin-45–positive cardiac cells that 
are capable of depolarizing and may represent a population of 
resident stem cells.42
Although direct injection into the myocardium represents the 
preferred delivery route to maximize stem cell retention in the 
infarcted heart, survival and long-term engraftment remain rather 
modest.43 Furthermore, different cell types might have dissimilar 
engraftment kinetics, depending on their ability to resist to the 
harsh environment of an ischemic heart and to establish retaining 
contacts with recipient’s cells. Here, we newly show that trans-
planted SVPs are endowed with higher incorporation rate com-
pared with CSCs. Furthermore, after combined injection, the 2 
cell types were localized distant from each other in the recipient’s 
heart. As a consequence, local promotion of cardiomyocyte re-
pair by CSCs may remain temporally and spatially disconnected 
from the SVP-induced neovascularization. Implemented delivery 
systems and tissue engineering approaches, allowing a stronger 
interaction in vivo, might be necessary to integrate those distinct 
reparative mechanisms into a synergic action.
Dual cell therapy delivered significant benefits in term of re-
duction of infarct size and arteriogenesis. The molecular and cel-
lular mechanisms for scar size reduction with cell therapy remain 
controversial. It is likely that each cell population used in the pres-
ent study has contributed in a distinct and complementary man-
ner, rather than through cooperation within a specific mechanism. 
Differentiation of CSCs into cardiomyocytes was a rare event, 
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whereas SVPs did not show any cardiomyogenic activity either 
in vitro or in vivo. Both SVPs and CSCs inhibit cardiomyocyte 
apoptosis and CSCs uniquely stimulate adult cardiomyocytes to 
re-enter the cell cycle. Prevention of cardiomyocyte loss in the 
area at risk and production of new cardiomyocytes may have 
therefore concurred in reducing the scar dimensions. The abil-
ity of cell therapy to stimulate endogenous CSCs to proliferate 
and differentiate is emerging as an exciting new mechanism of 
action.30 We newly report that intramyocardial injection of SVPs 
or CSCs, as a single or combined therapy, increases the abun-
dance of primitive c-Kit+ cells in the peri-infarct zone and that 
the conditioned medium of the 2 populations exerts a potent che-
moattractant activity on murine CSCs, without influencing their 
proliferation or viability. Vasculogenesis and enhanced blood 
supply to areas of hibernating myocardium are relevant in limit-
ing infarct extension. Our study indicates that SVP transplanta-
tion helps the development of capillary and arteriolar coronary 
vessels in the infarct border zone, with dual cell therapy enhanc-
ing the arteriogenic effect. SVPs express recognition binding 
sites that facilitate perivascular engraftment in vivo, through the 
establishment of robust interactions with cadherin-based adher-
ens junctions on the coronary endothelium.15 Here, we report the 
indirect support of transplanted SVPs on vascularization. In fact, 
we could not find evidence of SVP or CSC differentiation into 
endothelial cells. Nonetheless, single cell therapy with SVPs and 
dual cell therapy with SVPs and CSCs increased the proliferation 
of capillary endothelial cells and vascular smooth muscle cells, 
thus resulting in an expansion of large arterioles.
In conclusion, this study is the first to document the func-
tional, histological, and molecular interaction of combined cell 
therapy with human CSCs and SVPs. The 2 cell populations are 
therapeutically effective in a mouse model of MI and in combina-
tion they work better to reduce infarct size and collateralization. 
Combinatory approaches using stem cells from discarded surgical 
tissue may open unprecedented opportunities for cardiac repair.
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What Is Known?
t Preliminary evidence supports the feasibility and efficacy of cell ther-
apy with autologous cardiac stem cells (CSCs) in patients with myo-
cardial infarction (MI).
t Intramyocardial injection of human saphenous vein–derived pericytes 
(SVPs) supports reparative angiogenesis in a mouse model of acute MI, 
thereby promoting recovery of left ventricular function.
t Cell therapy with a combination of CSCs and bone marrow–derived 
mesenchymal stromal cells exerts additive effects in reducing the in-
farct size and improving the recovery of cardiac function in a swine 
model of cardiac ischemia–reperfusion.
What New Information Does This Article Contribute?
t Combined delivery of CSCs and SVPs in a mouse model of MI additively 
leads to a reduction in infarct size and an increase in arteriogenesis.
t CSCs and SVPs contribute to myocardial repair via complementary 
paracrine mechanisms; CSC promote cardiomyogenesis and SVPs 
vasculogenesis.
t In comparison with single cultures, cocultures of human CSCs and 
SVPs result in an increase in the release of the cardioprotective stromal 
cell–derived factor-1α (SDF-1α), likely because of the downregulation 
of dipeptidyl peptidase-4 (an stromal cell–derived factor-1–degrading 
enzyme) in CSCs.
Despite several clinical trials, an optimal stem cell–based strat-
egy for the treatment of the failing heart has remained elusive. 
Hence, combinations of cells with complementary features may 
provide synergistic effects improving therapeutic outcomes. 
Starting from this consideration, we tested the effects of simul-
taneous injection of human CSCs and SVPs in a mouse model 
of acute MI. We selected these 2 cell populations because CSCs 
can differentiate in cardiomyocytes and vascular cells, and as we 
have demonstrated previously, SVPs support reparative angio-
genesis in the infarcted heart, thereby promoting the recovery 
of left ventricular function. We found that in a murine model of 
MI, CSCs and SVPs act in a complementary fashion, promoting 
cardiomyogenesis and vasculogenesis, respectively. Importantly, 
when the cells were delivered together, we observed a reduction 
of infarct size and an augmentation of arteriogenesis. These find-
ings reinforce the concept that combined treatments using cells 
with complementary potential may improve the efficacy of stem 
cell therapy in patients with MI.
Novelty and Significance





LIST OF ABBREVIATIONS 
 
ANG1 - Angiopoietin-1 
ANG2 - Angiopoietin-2  
CSCs - cardiac stem cells !
DAPI - 4',6-diamidino-2-phenylindole  
EdU - 5-ethynyl-2’-deoxyuridine 
i.p. - intraperitoneal injection 
MI - myocardial infarction !
O.N. - over night, incubation of 16hrs at 4°C!
PBS - phosphate buffered saline !
PFA - paraformaldehyde!
RT - room temperature!
SDF-1 - stromal cells-derived factor 1!
SVPs - saphenous vein derived pericytes !






Experiments involving live animals were performed in accordance with the Guide for the Care and 
Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 
85-23, revised 1996) and with the approval of the British Home Office and the University of Bristol.  
Studies on human cells complied with the ethical principles stated in the ‘Declaration of Helsinki’. 
The use of human CSCs and SVPs was regulated by approvals from the Independent Ethics 
Committee of the University Hospital of Udine and South West-Bristol Central Research Ethics 
Committee. Informed written consent was obtained from patients.  
 
Cell isolation and culture 
CSCs: Discarded atrial specimens, weighing 3 to 6 g, were collected from hearts of healthy donors 
at the time of transplantation at the Cardiac Surgery Unit of the University Hospital of Udine (Italy).  
CSCs were isolated as described in1. Briefly, biopsies were collected in basic dissociation buffer 
(BDB)1 containing penicillin and streptomycin. Myocardial tissue was carefully dissected from 
adipose tissue, endocardium and pericardium using sterile tweezers and scalpel, and then washed 
in BDB and digested for 5-10 minutes with 0.04% Collagenase type II (Sigma-Aldrich, Dorset, UK) 
in BDB. Tissue aggregates were eliminated by passing the cell suspension through a 40µm cell 
strainer. Finally, cells were plated in human MesenCult proliferation medium (STEMCELL 
Technologies, Manchester, UK) with the addition of 1X penicillin and streptomycin (Life 
Technologies, Paisley, UK). Starting from the second passage, cells were cultured in MAPCs 
medium (prepared as in1) on plates coated with human fibronectin (10µg/mL) (Sigma-Aldrich, 
Dorset, UK).  
SVPs: Discarded saphenous vein specimens were collected from patients undergoing CABG 
surgery as previously described2,3. In brief, veins, collected in phosphate buffered saline (PBS) 
(Life Technologies, Paisley, UK) containing 1X penicillin and streptomycin (Life Technologies, 
Paisley, UK), were carefully dissected from surrounding tissues using a sterile scalpel and then 
thoroughly washed in excess PBS, containing antibiotics. Veins were then manually minced with a 
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scalpel before being incubated for 3-4 hours with 3.7mg/mL Liberase 2 (Roche, Basel, 
Switzerland), at 37°C in rotating tubes. The remaining aggregates were eliminated by passing the 
cell suspension through 30µm cell strainer. Cells were then incubated with anti-CD31 conjugated 
beads (Miltenyi, Bergisch Gladbach, Germany) for 30min at 4°C and passed through a magnetic 
column, following the manufacturer’s instructions. This allowed efficient removal of mature 
endothelial cells. After depletion of CD31 positive cells, remaining cells were further incubated with 
anti-CD34 beads (Miltenyi, Bergisch Gladbach, Germany) for 30min at 4°C and then processed to 
obtain purified CD34 positive cells. Sorted cells were cultured on plates coated with Fibronectin 
(10µg/mL) and gelatin (0.1%) (both from Sigma-Aldrich, Dorset, UK) in the presence of growth 
medium, EGM2 +2% FBS (Lonza, Gloucestershire, UK).  
All experiments were performed with CSCs and SVPs at passage 5-6. 
 
Flow cytometry (FACS) analysis 
SVPs and CSCs were stained for surface antigen expression using the following fluorochrome-
conjugated antibodies: anti-CD90, anti-CD34, anti-CD31 (BD biosciences, Oxford, UK), anti-CD45 
(Milteny, Bergisch Gladbach, Germany), anti-CD105 (Invitrogen, Paisley, UK), anti-CD44 
(eBioscience, Hatfield, UK). After cell detachment, incubation was performed for 20 min at room 
temperature (RT), in the dark. The c-Kit antigen required a different procedure as it was an 
unconjugated antibody. After the first incubation with the anti-c-Kit antibody (Dako, 30 minutes at 
37°C), cells were washed in PBS and incubated with a labelled secondary antibody for 20 minutes 
at 37°C.  
After staining, cells were washed in PBS and fluorescence was analyzed using a FACS Canto II 
flow cytometer and FACS Diva software (both BD Biosciences, Oxford, UK). To control for 
specificity, isotype matched antibodies were employed as negative controls. 
 
Cell characterization by immunofluorescence 
For characterization, CSCs and SVPs were seeded at a density of 5,000 cells/cm2 on 24-wells 
plate coverslips, fixed with 4% buffered paraformaldehyde (PFA) (Sigma-Aldrich, Dorset, UK) in 
PBS for 20min at RT and incubated with antibodies as specified in the table. For staining with c-Kit 
antibody, cells were fixed with PFA for 10 min at RT. Blocking was performed with 10% Goat 
Serum (GS) in PBS, for 30 mins at RT. 
For detection of intracellular antigens, cells were permeabilized for 10 min at RT with 0.1% (v/v) 
Triton X100 (Sigma-Aldrich, Dorset, UK) diluted in PBS, before to proceed with antibody staining. 
The table lists the antibody dilutions, incubation times (O.N.=overnight, 16hrs at 4°C) and 
temperatures employed. Incubations with primary and secondary antibodies were carried out in 
humid chambers. Nuclei were recognized by 4',6-diamidino-2-phenylindole (DAPI) staining. Cells 
were analyzed at a 400X magnification. Adobe Photoshop software was utilized to compose and 




Primary antibody Secondary antibody 
Oct-4 yes Abcam, 1:400, ON 4°C  Invitrogen, A488 Goat α-Rabbit, 1:200, 1h RT 
Sox-2 yes Millipore, 1:100, ON 4°C Invitrogen, A488 Goat α-Rabbit, 1:200, 1h RT 
Nanog yes Abcam, 1:100, ON 4°C  Invitrogen, A488 Goat α-Mouse, 1:200, 1h RT 
c-Kit no Dako, 1:40, 2hrs 37°C Invitrogen, A488 Goat α-Rabbit, 1:200, 1h RT 
PDGFRβ  no Santa Cruz, 1:50, ON 4°C Invitrogen, A488 Goat α-Rabbit, 1:200, 1h RT 





Differentiation assay toward the 3 cardiovascular lineages 
To test the differentiative potential of CSCs and SVPs toward the 3 cardiovascular lineages 
(cardiomyocytes, endothelial cells and vascular smooth muscle cells), 3 cell lines of each type  
were seeded in differentiation medium at a density of 5,000 cells/cm2, let to become confluent with 
media exchange every 3 days, for 14-21 days. The following differentiation methods and media 
were used:  
- endothelial differentiation: CFU-Hill Liquid Medium Kit from STEMCELL Technologies, 
Manchester, UK, or a medium enriched with human VEGF (vascular endothelial growth factor, 
PeproTech EC Ltd, London, UK) as described in (Cesselli et al., 2013)1;  
- cardiomyocyte differentiation: 2 different methods were employed. The first is based on the 
culture of cells with a medium containing ascorbic acid (Sigma-Aldrich, Dorset, UK), 10ng/mL 
human bFGF (basic fibroblast growth factor), 10ng/mL VEGF and 10ng/mL IGF-1 (insulin-like 
growth factor 1) (all from PeproTech EC Ltd, London, UK), as described in (Cesselli et al., 2013)1; 
the second one is characterized by an initial 3-day long phase of demethylation by 5 µM 5-aza-2'-
deoxycytidine (Sigma-Aldrich, Dorset, UK) and the following culture of cells with a medium 
containing ascorbic acid and 1ng/mL human TGF-β1 (transforming growth factor beta 1) 
(PeproTech EC Ltd, London, UK), as described in (Smits et al., 2009)4;  
- smooth muscle cells differentiation: differentiation medium added with 20ng/mL of human 
platelet-derived growth factor-BB (PDGF-BB, PeproTech EC Ltd, London, UK), as in (Cesselli et 
al., 2011)5. 
Cells were fixed with 4% PFA (Sigma-Aldrich, Dorset, UK) for 20 min at RT, permeabilized with 
0.1% TritonX100 (Sigma-Aldrich, Dorset, UK) in PBS for 10min at RT when required, and stained 
with antibodies, in humid chambers in the dark, as illustrated in the table. Nuclei were recognized 
by DAPI staining. Cells were analyzed at a 400X magnification. Adobe Photoshop software was 




Primary antibody Secondary antibody 
CD31 no Dako, 1:100, 2hrs 37°C Invitrogen, A488 Goat α-Rabbit, 1:200, 1h RT 
α-SMA yes Dako, 1:50, 2hrs 37°C Invitrogen, A488 Goat α-Rabbit, 1:200, 1h RT 
α-SA yes Sigma, 1:500, 1hr RT Invitrogen, A555 Goat α-Mouse, 1:200, 1h RT 
Connexin43 yes Santa Cruz, 1:40, 2hrs 37°C Invitrogen, A488 Goat α-Rabbit, 1:200, 1h RT 
MHC yes Abcam, 1:100 ON 4°C Invitrogen, A488 Goat α-Rabbit, 1:200, 1h RT 
 
 
RealTime PCR analysis of SVPs after cardiomyocyte differentiation  
To test the ability of SVPs to differentiate toward the cardiomyocyte lineage, total RNA was 
collected from n=3 lines of SVPs in basal culture conditions and after differentiation obtained with 
both the protocols described (see above). 
RNA was extracted using Qiagen MiRNeasy kit (Life Technologies, Paisley, UK). The expression 
of the cardiac markers Tbx5, Connexin43, cardiac troponin T (CNNI3), cardiac myosin heavy chain 
(Myh7), Islet1, NKX2.5 and RyR2 were evaluated by reverse transcription using the High Capacity 
RNA-to-cDNA kit (Life Technologies, Paisley, UK) followed by quantitative PCR-based 
amplification using TaqMan probes (Life Technologies, Paisley, UK). The expression of UBC was 
employed as housekeeping gene to normalize the expression levels. Quantitative PCR was 
performed on a LightCycler480 Real-Time PCR system (Roche Technologies, Basel, Switzerland). 
Quantitative PCR parameters for cycling were as follows: 50° C incubation for 2 min, 95° C for 10 
min, 40 cycles of PCR at 95° C for 15 s, and 65° C for 1 min. All reactions were performed in a 10 
µl reaction volume in triplicate. The mRNA expression level was determined using the 2−ΔCt 
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method.6 Values of gene expression are expressed as fold-change of differentiated cells with 
respect to basal cells. 
 
Labelling of cells with long term trackers 
For selected in vivo and in vitro experiments, CSCs and SVPs were stained respectively with the 
long term cell trackers VyBrant diO and VyBrant diL (Molecular Probes, Life Technologies, Paisley, 
UK). Briefly, diO and diL were diluted 1:1000 in PBS and incubated with confluent cells (adherent 
to the culture plate) for 5 min at 37°C and then on ice for further 15 min, in the dark. Cells were 
then washed with PBS and used for experiments. 
 
Mouse model of myocardial infarction and cell transplantation 
Two independent in vivo experiments were performed to test the short (14 days) and long (42 
days) follow-up after myocardial infarction (MI) and cell transplantation.  
MI was induced in 8 week-old female SCID Beige mice (Charles River) by permanent ligation of 
the left anterior descending coronary artery (LAD) as described in our earlier studies7-9. In brief, 
with mice under anesthesia (2,2,2 tribromo ethanol, 0.3gm/kg, i.p.) and artificial ventilation, the 
chest cavity was opened and, after careful dissection of the pericardium, LAD was permanently 
ligated using a 7-0 silk suture. This was followed by injection of either SVPs (300,000 cells, n=9 
cell lines) (n=11 and 6 animals, for the short and long follow-up respectively) or CSCs (300,000 
cells, n=9 cell lines) (n=12 and 7 animals) alone or in combination (300,000 cells for each type, 
n=9 cell lines for each type (n=12 and 7 animals)) at 3 different sites along the infarct border zone 
with final volume of 5µL at each site. Cells were resuspended in PBS for injection and were all at a 
passage 5 or 6 of culture. Vehicle animals (n=14 and 7 for 14 days and 42 days follow-up, 
respectively) received PBS injection in the similar manner. Sham-operated mice (n=6), in which the 
chest was opened without MI induction or any therapy, were used as control. 
For the short-term recovery experiment (14 days post-MI), a selected number of animals were 
transplanted with cells pre-labelled with the long term cell trackers VyBrant-Dil (for SVPs) and 
VyBrant-diO (for CSCs) (see above) to allow the recognition of human cells in the mouse heart. 
Another group of animals received unlabeled CSCs and SVPs and i.p. injection of 360µg EdU 
(resuspended in 100µL of sterile PBS, both from Life Technologies, Paisley, UK) every 2 days, for 
all the recovery period, in order to assess the cumulative vasculogenesis and cardiomyogenesis 
during the 14 days post-MI period.  
We previously determined the optimal dose of SVPs and CSCs for injection in the animal heart, in 
order to reach positive results at the functional outcome10,11. We decided to inject the double 
amount of cells in the combined SVP+CSC therapy in order to obtain the maximum beneficial 
effects given by each cell population. 
Animals were allowed to recover with aseptic precautions and received analgesic medication 
(Buprenorphine, 0.1mg/kg s.c.) to reduce post-operative pain. 
 
Echocardiography and hemodynamic measurements 
Measurements of dimensional and functional parameters were performed before and at 14 and 
42 days after MI using a high-frequency, high resolution echocardiography system (Vevo 770, 
Visual Sonics, Toronto, Canada). Briefly, mice were anesthetized using tribromo-ethanol and 
transferred to an imaging stage equipped with a warming pad for controlled maintenance of 
mouse body temperature at 37°C and a built-in electrocardiography system for continuous heart 
rate (HR) and respiratory rate monitoring. The thickness of the left ventricle (LV) was measured at 
the level of the papillary muscles in parasternal short axis at end-systole and end-diastole. LV 
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ejection fraction (LVEF) and fractional shortening (LVFS) were determined as described by De 
Simone et al.8,9,12 Following the final echocardiography measurement on day 14 and 42 post-MI, 
under anesthesia, intraventricular pressure measurement was done using a high-fidelity 1.4F 
transducer tipped catheter (Millar Instruments, Houston, TX, USA) inserted into the left ventricle 
through right carotid artery. The position of transducer into the heart was confirmed by the rapid 
deflection of the diastolic pressure wave without any change in systolic pressure. After 5 min 
stabilization, baseline data were collected, including the HR, Peak LV systolic pressure (LVESP), 
LV end-diastolic pressure (LVEDP), and maximal rates of LV pressure rise (dP/dtmax) and fall 
(dP/dtmin).8,9,13 To calculate pressure volume relationship, the recording from Millar catheter was 
synchronized with echocardiography measurements as per manufacturer instructions.7-9 
 
Samples processing for histology 
After completion of hemodynamic measurements, hearts were stopped in diastole by 
intramyocardial injection of 0.1M cadmium chloride. Hearts were then washed free of blood by 
retrograde perfusion with PBS-2% EDTA solution, followed by fixation with freshly prepared ice-
cold 4% w/v PFA (Sigma-Aldrich, Dorset, UK) in PBS, (1) shortly in perfusion and (2) for 24 hours 
at 4°C after explantation of the organ. Then, hearts were washed with PBS and cryoprotected 
overnight at 4°C in PBS containing 10% w/v sucrose (Sigma-Aldrich, Dorset, UK). Tissues were 
then cut transversally in the middle in order to obtain 2 separate portions: the apex/middle and 
middle/base of the heart, and were embedded in Tissue-Tek compound (OCT) and frozen at -
80°C.  
For a selected number of samples, the atria and the right ventricle were separated from the left 
ventricle, and the mass of this latter has been measured before cryoprotection with Sucrose and 
cryopreservation in OCT.  
 
Immunohistochemistry on ventricular sections 
Immunohistochemistry analysis was performed on left ventricular cryosections (8µm thick) post-
fixed with 4% PFA (Sigma-Aldrich, Dorset, UK) in PBS, for 20 min at RT, or with ice-cold Acetone, 
for 10 min at -20°C, followed by permeabilization with 0.1% Triton X-100 in PBS, for 10 min at RT.  
Slides used for histology were pre-treated with VECTABOND reagent (Vector Laboratories, UK).  
 
Assessment of human cell engraftment and in vivo differentiation 
For the detection of non-labelled human cells in the mouse hearts at 14 and 42 days post-MI, n=3-
4 sections were incubated with a mouse monoclonal anti-Human Nuclei antibody (Millipore, UK, 
1:100, O.N. 4°C), followed by goat-anti mouse secondary antibody conjugated with Alexa Fluor 
568 (Invitrogen, UK, 1:200, 1h RT). A human myocardial sample was employed as positive control 
for the labelling efficiency of the antibody. To assess the cardiomyocyte differentiation, sections 
were incubated with a mouse monoclonal anti-α-sarcomeric actin (Sigma-Aldrich, Dorset, UK, 
1:200, 1h 37°C) followed by goat-anti mouse IgM secondary antibody conjugated with Alexa Fluor 
647 (Invitrogen, UK, 1:200, 1h RT). For endothelial markers, sections were incubated either with a 
sheep anti-human CD34 (DAKO, UK, 1:100, ON 4°C) followed by a donkey anti-sheep secondary 
antibody conjugated with Alexa Fluor 488 (Invitrogen, UK, 1:200, 1h RT), or with biotinylated 
Isolectin B4 (Invitrogen, UK, 1:200, ON 4°C) followed by streptavidin Alexa Fluor 488 (Invitrogen, 
UK, 1:200, 1h at RT). Nuclei were recognized by DAPI staining. 
In 14 days post-MI samples, when pre-labelled, injected SVPs were identified by the Vybrant Dil 





Spectral Analysis for Human Nuclei immunolabelling 
To assess the specificity of the Human Nuclei immunolabelling protocol, spectral analysis was 
performed with a TCS-SP2 confocal microscope (Leica, Wetzlar, Germany) using the lambda 
acquisition mode, as in5. Lens and corresponding numerical aperture were 63X and 1.4, 
respectively. 8µm SVP- and CSC-transplanted heart cryosections, cut along the infarcted left 
ventricle, were labelled with a mouse anti-Human Nuclei antibody 
followed by AlexaFluor 568 goat anti-mouse secondary antibody (see above for the labelling 
protocol). Nuclei were stained with DAPI. The emission signal for AlexaFluor 568 
was excited at a wavelength of 513 nm with an argon laser, and the fluorescence emitted from 
the tissue was recorded over the interval from 515 to 750 nm. A series of 30 images were acquired 
at a 7.9 nm intervals.  
This operation was followed by both the calculation of the emission spectra and by the spectral 
dye separation, to selectively distinguish the specific Dye emission (corresponding to Human 
Nuclei) from the aspecific one (corresponding to lipofuscines). Sampling consisted of at least 15 
Human Nuclei-positive cells and 15 Lipofuscines, randomly collected from SVP- and CSC-
injected hearts. Additionally, 15 fluorescent signals corresponding to the background 
autofluorescence of the tissue, present in the same samples, were used as control, to 
discriminate background autofluorescence from specific labeling. Finally, graphs plotting mean 
pixel intensity and the emission wavelength of the lambda stack were generated. 
 
Vascular density profiling 
For capillary density, n=3 5µm thick LV cryosections were incubated with biotinylated Isolectin B4 
(Invitrogen, UK, 1:200, ON 4°C, in a humidified chamber), followed by streptavidin Alexa Fluor 488 
(Invitrogen, UK, 1:200, 1h at RT). For arteriole density, the same sections were probed with anti-
mouse α-smooth muscle cell actin antibody conjugated with Cy3 (Sigma chemicals, UK, 1:400, 1h 
at RT). Capillaries and arterioles were calculated in 10 fields (at a X400 magnification) in the peri-
infarct myocardium, and the final data expressed as the number of capillaries or arterioles per 
square millimeter. Arterioles were also categorized according to their luminal size.7,14 The analysis 
was performed using the free software ImageJ (http://imagej.nih.gov/ij/). Adobe Photoshop 
software was utilized to compose and overlay the images (Adobe). 
 
Cardiomyocyte proliferation and apoptosis 
For analysis of proliferation, n=2 sections were incubated with rabbit polyclonal Ki67 antibody 
(Abcam, UK, 1:500, O.N. 4°C), followed by goat-anti rabbit secondary antibody conjugated with 
Alexa Fluor 549 (Invitrogen, UK, 1:400, 1h 37°C), and mouse monoclonal α-sarcomeric actin 
(Sigma, 1:200, 1h 37°C) followed by goat-anti mouse secondary antibody conjugated with Alexa 
Fluor 488 (Invitrogen, UK, 1:500, 1h 37°C). Nuclei were recognized by DAPI staining. The data 
were expressed as fraction of Ki67pos myocyte nuclei in the border zone.  
Cardiomyocyte apoptosis was quantified by the terminal deoxynucleotidyl-transferase (TdT)-
mediated dUTP nick-end labeling (TUNEL) technique (in situ cell death detection kit Fluorescein, 
Apoptag, Millipore, Germany). Following the treatment of n=2 slides with proteinase K (Sigma, 
15µg/ml, 10min at RT), the TUNEL assay was performed according to the manufacturer’s 
instructions. Finally sections were stained with DAPI to recognize nuclei. The data were expressed 
as fraction of TdTpos myocytes nuclei in peri-infarct zone. Sections were analysed at a 400X 






Identification of cardiac stem cell pool in myocardium 
For identification of the cardiac stem cell pool in the myocardium, n=3 sections were incubated 
with a goat polyclonal antibody specifically reactive with the mouse c-Kit antigen (R&D, USA, 
1:100, 2h at 37°C), followed by donkey anti-goat Alexa Fluor 555 antibody (Invitrogen, USA, 
1:800); mouse monoclonal mast cell tryptase (Abcam, USA, 1:400, 2h at 37°C), followed by 
donkey anti-mouse Alexa Fluor 488 antibody (Invitrogen, USA, 1:800); and mouse monoclonal α-
sarcomeric actin (Sigma Chemicals, Italy, 1:200, 1h at 37°C), followed by donkey anti-mouse 
DyLight 649 antibody (Invitrogen, USA, 1:400). Nuclei were recognized by DAPI staining. The 
data were expressed as the density of cells in peri-infarct zone. Sections were analysed at a 630X 
magnification. Adobe Photoshop software was utilized to compose and overlay the images 
(Adobe). 
 
Assessment of cumulative vasculogenesis and myocardial proliferation 
EdU-treated hearts were used for this analysis. n=3 sections were first processed using the Click-
IT EdU 488 or 555 Imaging kit (Life Technologies, Paisley, UK) to reveal EdU incorporation, 
according to the manufacturer’s instructions. Sections were then stained for alpha-sarcomeric 
actin, Isolectin-B4 or alpha-SMA, as already indicated above. Nuclei were recognized by DAPI 
staining. Sections were analysed at a 400X magnification. Data were expressed as fraction of 
EdUpos cardiomyocyte nuclei or as the number of capillaries or arterioles including 
endothelial/smooth muscle cells EdU-positive nuclei per square millimeter, in the border zone. 
Arterioles were also categorized according to their luminal size. 
 
Assessment of infarct size and myocardial fibrosis 
Infarct size was evaluated in n=3 not consecutive sections cut at different levels along the 
infarcted left ventricle, by Azan Mallory staining as in7. Two different methods (area and length-
based measurements) were applied in 14 and 42 days post-MI samples, as previously explained 
in15. Infarct size is expressed as the percentage of the left ventricle sectional area occupied by the 
fibrotic scar.  
Myocardial interstitial fibrosis was analyzed in n=3 sections by Azan Mallory staining. Fifteen 
fields were randomly evaluated in the spared myocardium at a 400X magnification. Data are 
expressed as the percentage of fibrotic area.  
Adobe Photoshop software was utilized to compose and adjust the contrast of the images 
(Adobe). Analysis was performed using the free software ImageJ (http://imagej.nih.gov/ij/). 
 
Assessment of cardiomyocyte hypertrophy and nuclear density 
Cardiomyocyte cross sectional area (CSA) and cardiomyocyte nuclear density were evaluated in 
n=3 not consecutive sections cut at different levels along the infarcted left ventricle. Sections were 
incubated with an Alexa Fluor 488-conjugated anti-Wheat Germ Agglutinin antibody (Invitrogen, 
UK, 1:100, 30 min RT) and with a mouse monoclonal anti-α-sarcomeric actin antibody (Sigma, 
UK, 1:200, 1h 37°C) followed by goat-anti mouse IgM secondary antibody conjugated with Tritc 
(Invitrogen, UK, 1:200, 1h RT). Nuclei were recognized by DAPI staining. Sections were analysed 
at a 400X magnification. Analysis were performed using the free software ImageJ 
(http://imagej.nih.gov/ij/). For each sample, CSA was measured in 100 cardiomyocytes in which 
the nucleus was centrally located within the cell, in both the border peri-infarct zone and in the 
remote zone. The average regional cross-sectional area and regional myocyte nuclear density per 





Collection of cell supernatants for secretome and in vitro studies 
Confluent CSCs or SVPs or CSCs+SVPs were incubated with serum-free EGM-2 medium (Lonza, 
Gloucestershire, UK) for 48 hrs, in normoxic (20% O2) or hypoxic (2% O2) culture conditions. 1mL 
of medium was added to the cells for every 10cm2 of the plate surface. The same number of CSCs 
and SVPs were initially seeded in the single and combined cultures, so that in these latter the 
number of cells was two-fold respect to the single cell cultures and followed the ratio of 1:1 as for 
the cell transplantation in the mouse hearts. 
To mimic the in vivo ischemia situation, all the conditioned media employed for in vitro experiments 
(with cardiomyocytes, mouse CSCs and HUVECs) were collected incubating cells in hypoxia. Cell 
supernatants were collected, centrifuged at 1,000xg for 10 minutes at 4°C and stored at -80°C until 
use. 
 
Analysis of cell secretome by ELISA 
Human VEGF (vascular endothelial growth factor), bFGF (basic fibroblasts growth factor), HGF 
(hepatocyte growth factor), SCF (stem cell factor), ANG1 (Angiopoietin-1), ANG2 (Angiopoietin-2), 
SDF-1 (stromal cells-derived factor 1) and CD26/DPP-4 released in cell supernatants in normoxic 
and/or hypoxic culture (collected as described above) were dosed using DuoSet Development 
System by R&D or CD26/DPP-4 ELISA kit from Sigma-Aldrich, following manufacturer’s 
instructions. The amounts of all factors were expressed normalizing the data for the number of the 
cells at the end of the collection time and for the time of incubation.  
Evaluation of transcriptional regulation of secreted factors in CSCs and SVPs 
To evaluate if the release of SDF-1, ANG1, ANG2 and DPP-4 by co-cultures of CSCs and SVPs is 
regulated at the transcriptional level, confluent cultures of CSCs (n=3-4) and SVPs (n=3-5) were 
incubated for 6 hours with EGM-2 medium conditioned by the other cell type (n=3 CSCs or n=3 
SVPs) for 48hrs in normoxia or hypoxia. Unconditioned medium (UCM) was used as control.  
At the end of the incubation period, total RNA was collected and extracted using Qiagen MiRNeasy 
kit (Life Technologies, Paisley, UK). The expression of SDF-1, Angiopoietins and DPP-4 genes 
were evaluated by reverse transcription using the High Capacity RNA-to-cDNA kit (Life 
Technologies, Paisley, UK) followed by quantitative PCR-based amplification using TaqMan 
probes (Life Technologies, Paisley, UK). The expression of UBC was employed as housekeeping 
gene to normalize the expression levels. Quantitative PCR was performed on a 
LightCycler480 Real-Time PCR system (Roche Technologies). Quantitative PCR parameters for 
cycling were as follows: 50° C incubation for 2 min, 95° C for 10 min, 40 cycles of PCR at 95° C for 
15 s, and 65° C for 1 min. All reactions were performed in a 10 µl reaction volume in triplicate. The 
mRNA expression level was determined using the 2−ΔCt method.  
 
MicroRNA-132 expression in conditioned media 
The release of miR-132 was investigated in CSCs (n=3), SVPs (n=3) and co-coltures of 
CSCs+SVPs (n=3), in normoxic and hypoxic culture conditions. For samples collection, 200µL of 
medium was added to 1mL of QIAzol lysis reagent (Qiagen, Venlo, Netherlands). RNA was 
extracted using Qiagen MiRNeasy kit (Qiagen, Venlo, Netherlands). Extracted total RNA was 
reverse-transcribed using specific primers provided with the Taqman miRNA assay and MicroRNA 
Reverse Transcription Kit (Life Technologies, Paisley, UK). A microRNA synthetic spike was used 
to assess microRNA isolation efficiency and act as an internal control. Caenorhabditis 
elegans miRNA-39-3p (Life Technologies, Paisley, UK) was added to the conditioned media prior 
to RNA extraction. The synthetic spike and target genes were Caenorhabditis elegans miRNA-39-
3p and MicroRNA -132-3p. 
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Quantitative PCR was performed on a LightCycler480 Real-Time PCR system (Roche 
Technologies, Basel, Switzerland). Quantitative PCR parameters for cycling were as follows: 50° C 
incubation for 2 min, 95° C for 10 min, 40 cycles of PCR at 95° C for 15 s, and 60° C for 1 min. All 
reactions were performed in a 10 µl reaction volume in triplicate. The mRNA expression level was 
determined using the 2−ΔCt method. One-way ANOVA and Dunnet’s post-test multiple comparison 
test using mean values and standard error were used to compare results. These were performed 
on all the fold change means in all groups assessed, allowing the significance of multiple means to 
be assessed. 
Co-culture assays: in vitro interaction between SVPs and CSCs. 
1- EdU proliferation assay 
CSCs (n=3) and diL-labelled SVPs (n=3) were seeded in single or co-cultures in EGM-2 medium 
added of 2% FBS (both from Lonza, Gloucestershire, UK), on coated coverslips in 24-well plates. 
For co-cultures, the same number of CSCs and SVPs in single cultures was seeded, so that the 
final number of cells was two-fold respect to the single cell cultures, and followed the ratio 1:1 
between cells. After incubation for 20 hrs in presence of EdU in the culture medium, cells were 
fixed with buffered 4% PFA (Sigma-Aldrich, Dorset, UK) in PBS for 15min at RT and stained 
following manufacturer’s instructions (Click-iT® EdU Imaging Kit, from Invitrogen, Paisley, UK). 
Nuclei were stained with DAPI. Experiments were performed in duplicate. Cells were analysed at a 
400X magnification and the percentage of EdU+ cells was determined for each cell population. 
2- Tunel apoptosis assay with CSCs and SVPs in contact 
CSCs (n=3) and diL-labelled SVPs (n=3) were seeded in single or co-cultures in FBS free EGM-2 
medium (both from Lonza, Gloucestershire, UK), on coated coverslips in 24-well plates. After 48 
hrs of starvation, cells were fixed with 1% PFA (Sigma-Aldrich, Dorset, UK) in PBS for 10 min at 
RT and TUNEL assay was performed following manufacturer’s instructions (in situ cell death 
detection kit Fluorescein, Apoptag, Millipore, Germany). A negative and positive (treatment of cells 
with Dnase) control were included. Nuclei were stained with DAPI. Experiments were performed in 
duplicate. Cells were analyzed at a 400X magnification and the percentage of TdT+ cells was 
determined for each cell population. 
3- Tunel apoptosis assay with CSCs and SVPs kept separated by a membrane 
n=3 CSCs and n=3 SVPs lines were co-cultured (in all the possible combinations of CSCs+SVPs) 
using 24MW plates transwell membrane inserts with 0.4µm pores (CORNING, UK), that allow to 
grow different cells together but without contacts between cells. SVPs and CSCs cultured alone 
were used as control. 20,000 cells of one cell type were seeded on the bottom of the well and 
20,000 cells of the other cell type were added on the membrane. Cells were incubated with serum 
free EGM-2 for 48hrs. At the end of the starvation period, cells seeded on the bottom of the wells 
were fixed with 1% PFA (Sigma-Aldrich, Dorset, UK) in PBS for 10 min at RT and TUNEL assay 
was performed according to the manufacturer’s instructions (in situ cell death detection kit 
Fluorescein, Apoptag, Millipore, Germany). A negative and positive (treatment of cells with Dnase) 
control were included. Nuclei were stained with DAPI. Experiments were performed in duplicate. 
Cells were analyzed at a 200X magnification and the percentage of TdT+ cells was determined for 
each cell population. 
 
Paracrine effects of CSCs and SVPs on isolated rat cardiomyocytes: apoptosis assay. 
Cardiomyocytes were isolated from adult male rats. Animals were killed by stunning and cervical 
dislocation prior to dissection of the heart. Ventricular cardiomyocytes were isolated by the 
Langendorff method, using collagenase perfusion. At the end of the isolation procedure, Calcium 
was reintroduced gradually in the cell suspension to reach a concentration of 1.8 mM. 
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Cardiomyocytes were then plated at a density of 10,000 cells/cm2 on murine laminin (5µg/cm2, 
Sigma-Aldrich, Dorset, UK) coated 96-well plates, in a myocyte culture medium composed as 
follows: medium 199, 2g/L BSA, 2% FBS, 2mM Carnitine, 5mM Creatine, 5mM Taurine, 1mM 
Butanedione and antibiotics (all from Sigma-Aldrich, Dorset, UK), pH=7.35, and incubated for 1hr 
at 37°C, 5% CO2 to allow attachment to culture dish. Then culture medium was replaced with fresh 
one and cells were incubated for 4 more hours. 
Cardiomyocytes were then subjected to Simulated Ischemia (SI) for 1 hr by replacing the medium 
with an “ischemia buffer” composed as follows: 118 mM NaCl, 24 mM NaHCO3, 1.0 mM NaH2PO4, 
2.5 mM CaCl2-2H2O, 1.2 mM MgCl2, 20 mM sodium DL- lactate, 16 mM KCl, 10 mM 2-deoxy-D-
glucose (all from Sigma-Aldrich, Dorset, UK), pH=6.2, and incubating cells at 37°C, 1% O2 and 5% 
CO2. ReOxygenation (RO) was then accomplished incubating the cells for 17h at 37°C, 5%CO2, in 
cardiomyocyte medium conditioned by CSCs (n=3), SVPs (n=3) or co-cultured SVPs+CSCs (n=3) 
and diluted 1:2 with fresh medium prior to incubation with cardiomyocytes. Unconditioned 
cardiomyocyte medium was employed as control. To validate the pro-apoptotic effect of the SI/RO 
protocol employed, control cardiomyocytes were also cultured in normoxic conditions (without 
SI/RO). At the end of the reoxygenation period, the activity of caspase 3/7 in cardiomyocytes was 
evaluated employing the Caspase-Glo 3/7 assay (Promega, United Kingdom), following 
manufacturer’s instructions. Experiments were performed in quadruplicate. Caspase activity in 
treated cardiomyocytes is expressed as fold change of caspase activity in cells treated with UCM. 
To test the purity of isolated cells, cardiomyocytes were washed with PBS and fixed with 4% PFA 
(Sigma-Aldrich, Dorset, UK), in PBS for 20 minutes at RT, permeabilized using 0,1% Triton-X100 
in PBS (Sigma-Aldrich, Dorset, UK), 10 min at RT, and stained with an anti-alpha sarcomeric 
actinin antibody (Sigma, mouse monoclonal, 1:500 dilution, 1hr 37°C) followed by incubation with 
an Alexa555 goat-anti-mouse secondary antibody (Invitrogen, 1:200 dilution in PBS, 1hr at room 
temperature). Nuclei were stained with DAPI. Cells were analyzed at a X400 magnification. 
 
Paracrine effects of CSCs and SVPs on isolated mouse cardiac Sca-1+ cells. 
Sca-1+ cells were isolated from n=5 CD1 mouse (Charles River) hearts using the Cardiac Stem 
Cells Isolation Kit (Millipore, Germany) following manufacturer’s instructions. Cells were cultured 
and expanded in DMEM (Invitrogen, Paisley, UK) + 5% FBS (Life Technologies, Paisley, UK) until 
use. 
To test the purity of isolated cells, these latter were seeded in 8-chamber slides coated with 
Fibronectin (10µg/mL) and gelatin (0.1%) (both from Sigma-Aldrich, Dorset, UK), cultured and 
fixed with 4% PFA (Sigma-Aldrich, Dorset, UK) in PBS for 20 minutes at RT; cells were stained 
with a Tritc-conjugated antibody against mouse Sca-1 (BD biosciences, Oxford, UK), 1:20 
dilution, incubated for 1hr at 37°C. Nuclei were stained with DAPI. Cells were analyzed at a X400 
magnification. Adobe Photoshop software was utilized to compose the images (Adobe). 
BrdU proliferation assay 
3,000 Sca-1+ cells were seeded in each well of a 96-well plate and incubated for 16 hrs with EGM-
2 medium (Lonza, Gloucestershire, UK) conditioned by CSCs (n=3), SVPs (n=3) or co-cultured 
SVPs+CSCs (n=3) and additioned of 5% FBS (Lonza, Gloucestershire, UK) and BrdU (10µmol/L). 
Unconditioned EGM-2 was employed as control. After this period, the incorporation of BrdU by 
cells was measured using a BrdU assay kit from Roche Technologies, Basel, Switzerland, 
according to the manufacturer's instructions. Briefly, cells were fixed and made permeable with 
FixDenat solution for 20min, then incubated with monoclonal anti-BrdU peroxidase-conjugated 
antibody (anti-BrdU-POD) for 90min. Bound anti-BrdU-POD was detected by a substrate reaction, 
then quantified by an ELISA plate reader. Experiments were performed in triplicate. Proliferation in 
treated groups is expressed as fold change of proliferation in cells treated with UCM. 
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Caspase 3/7 apoptosis assay 
3,000 Sca-1+ cells were seeded in each well of a 96-well plate and incubated for 48 hrs with FBS-
free EGM-2 medium (Lonza, Gloucestershire, UK) conditioned by CSCs (n=3), SVPs (n=3) or co-
cultured SVPs+CSCs (n=3). Unconditioned EGM-2 was employed as control. After this period, the 
activity of caspase 3/7 was evaluated employing the Caspase-Glo 3/7 assay (Promega, United 
Kingdom), following manufacturer’s instructions. Experiments were performed in quadruplicate. 
Caspase activity in treated groups is expressed as fold change of caspase activity in cells treated 
with UCM. 
 
Migration toward CSC and SVP conditioned medium 
To test the capacity of CSC and SVP secretome to induce the migration of Sca-1+ CSCs,  40,000 
mouse Sca-1+ CSCs were seeded in 24-well plates on a 6.5mm Transwell® with 5.0µm Pore 
Polycarbonate Membrane Insert (Corning, UK), in serum-free EGM-2 medium (Lonza, 
Gloucestershire, UK). In the bottom of the wells, 0.5 mL of CSCs (n=3), SVPs (n=3) or co-cultured 
SVPs+CSCs (n=3) conditioned medium was added, as a stimulus to induce Sca-1+ CSC migration. 
Serum-free unconditioned EGM-2 was used as control. Cells were incubated for 8 hrs at 37°C. At 
the end of this period, the membrane inserts were washed with PBS, fixed with 4% PFA (Sigma-
Aldrich, Dorset, UK) in PBS for 20 min at RT, stained with DAPI and mounted on a slide. 
Membranes were analysed with an epifluorescence microscope at a 200X magnification; 10 fields 
were randomly acquired and migrated cells counted. No cells were detectable in the lower 
chamber of the 24-well plate. Migrated cells were expressed as percentage of total cells. 
Experiments were performed in duplicates. 
 
In vitro matrigel assay with HUVECs 
The capacity of CSC, SVP and co-cultured CSC+SVP secretomes to induce the formation of an 
endothelial cell network of human umbilical vein endothelial cells (HUVECs, Cambrex/Lonza) was 
evaluated using an extracellular matrix (ECM) gel assay (BD Bioscience, Oxford, UK). 70 µL of 
matrigel was added into each well of an ice-cold 96-well plate and incubated for 30 minutes at 
37°C. This was performed on ice. 8000 HUVECs at passage 5 were resuspended in 100 µL of 
conditioned medium from CSCs (n=5), SVPs (n=5) and CSCs+SVPs (n=5) previously diluted 1:1 
with new fresh EGM-2 medium supplemented with 5% FBS (Lonza, Gloucestershire, UK). The 
cells were added on the top of the gelified matrigel (100 µL/well) and incubated for 6 hours at 
37°C, 5% CO2. Unconditioned EGM-2 was used as control.  
The assay was performed in quadruplicate. Network formation was analyzed in an Axiovert 
microscope (Zeiss); an image for each well was acquired at a magnification of 50X. For 
quantification, the length of the networks was measured using the software ImageJ (http:// 
rsb.info.nih.gov/ij/) and the cumulative tube length (in mm) per field was calculated. 
 
BrdU proliferation assay with HUVECs 
1,500 HUVECs were seeded in each well of a 96-well plate and incubated for 40 hrs with EGM-2 
medium (Lonza, Gloucestershire, UK) conditioned by CSCs (n=3), SVPs (n=3) or co-cultured 
SVPs+CSCs (n=3) and additioned of 5% FBS (Lonza, Gloucestershire, UK) and BrdU (10µmol/L). 
Unconditioned EGM-2 was employed as control. After this period, the incorporation of BrdU by 
cells was measured using a BrdU assay kit from Roche Technologies, Basel, Switzerland, 
according to the manufacturer's instructions. Briefly, cells were fixed and made permeable with 
FixDenat solution for 20min, then incubated with monoclonal anti-BrdU peroxidase-conjugated 
antibody (anti-BrdU-POD) for 90min. Bound anti-BrdU-POD was detected by a substrate reaction, 
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then quantified by an ELISA plate reader. Experiments were performed in triplicate. Proliferation in 
treated groups is expressed as fold change of proliferation in cells treated with UCM. 
 
In vitro matrigel assay with SVPs and CSCs 
The capacity of SVPs, CSCs and co-culture of SVP+CSC (n=4 for each cell type) to form tubular 
networks was evaluated using an extracellular matrix (ECM) gel assay (BD Bioscience, Oxford, 
UK). 70 µL of matrigel was added into each well of an ice-cold 96-well plate and incubated for 30 
minutes at 37°C. This was performed on ice. 4,000 SVPs, 4,000 CSCs or 4,000 SVPs + 4,000 
CSCs at passage 5 were resuspended in 100 µL of EGM-2 medium supplemented with 2% FBS 
(Lonza, Gloucestershire, UK). The cells were added on the top of the gelified matrigel (100 µL/well) 
and incubated for 5 hours at 37°C, 5% CO2. 
The assay was performed in triplicate. Network formation was analyzed in an Axiovert microscope 
(Zeiss); an image for each well was acquired at a magnification of 50X. For quantification, the 
length of the networks was measured using the software ImageJ and the cumulative tube length (in 
mm) per field was calculated. 
 
Statistics 
Results are expressed as mean±SEM. After the normality test, comparison of multiple groups was 
performed by 1 way ANOVA or Kruskal-Wallis test as appropriate, followed respectively by 
Bonferroni or Dunns post-test. Difference between two groups was analyzed using t-test (paired or 
unpaired as appropriate). A P value of <0.05 was considered statistically significant. 
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Online figure I. CSCs characterization. (A) Flow cytometry analysis of c-Kit expression 
in CSC lines employed for in vitro and in vivo experiments. Isotype control IgG staining 
profiles are shown by the red border line histograms, while specific antibody staining profiles 
are shown by full green histograms. Data are expressed as means±SEM (n=12). (B) 
Immunofluorescence images showing the CSC plasticity toward the 3 cardiovascular 
lineages. When cultured for 2-3 weeks in specific inductive media, CSCs are able to 
differentiate in endothelial cells expressing CD31, vascular smooth muscle cells positive for 
the contractile protein alpha-smooth muscle actin (α-SMA), and cardiomyocyte-like cells 
expressing the contractile filament MHC (myosin heavy chain). Nuclei are shown by the blue 
fluorescence of 4’, 6-diamidino-2-phenylindole (DAPI). Scale bar: 50µm. 
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Online figure II. Differentiation of SVPs toward the cardiomyocyte lineage. At 
immunofluorescence analysis, undifferentiated SVPs express Connexin-43 (in green) but 
are negative for the cytoplasmic protein α-Sarcomeric Actin (A), while after culture for 21 
days with an inductive medium, cells express α-Sarcomeric Actin (red) (B). Nuclei are 
shown by the blue fluorescence of 4’, 6-diamidino-2-phenylindole (DAPI). Bar graphs show 
the results of qPCR analyses of Connexin-43 and Tbx5 mRNA levels in SVPs (n=3 
biological replicates) before and after induction of cardiomyocyte differentiation using the 
protocols described in Beltrami et al., 2007 (C) and Smits et al., 2009 (D) (see methods). 
Data are presented as mean±SEM. 
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Online figure III. Effect of single or combined cell therapy on echocardiographic and 
hemodynamic parameters 42 days post-myocardial infarction (MI). SCID/Beige 
immunodeficient mice were intramyocardially injected with SVPs (300,000cells/heart), CSCs 
(300,000cells/heart), SVPs+CSCs (300,000cells of each type/heart) or Vehicle at the 
occasion of MI induction and measurements were performed 42 days thereafter. Sham 
operated mice were included as control. LVID, left ventricle internal diameter; LVESV, LV 
end-systolic volume; LVEDV, LV end-diastolic volume; SV, stroke volume; CO, cardiac 
output; LVEF, LV ejection fraction; FS, fractional shortening; LVAW, LV anterior wall; 
LVESP, LV end-systolic pressure; LVEDP, left ventricle end-diastolic pressure; s, systole; d, 
diastole. Data are presented as mean±SEM (n=6-7 mice per group). #p<0.05, ##p<0.01, 
###p<0.001, ####p<0.0001 vs. Sham; *p<0.05, **p<0.01 vs. Vehicle. 
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Online figure IV. Engraftment and differentiation of CSCs and SVPs in the mouse 
heart at 14 days post-MI. Confocal images showing human cells engraftment in the mouse 
heart. (A): SVPs showed with the red fluorescence of diL and (B): CSCs showed with the 
green fluorescence of diO. α-Sarcomeric Actin labels cardiomyocyte cytoplasm and is 
showed in white in (A) and in magenta in (B). Nuclei (DAPI) are depicted in blue. (C-F) 
Human cells are recognised by fluorescent immunostaining with an anti-human nuclei 
antibody. SVPs nuclei, identified by white arrows, are depicted in red (C&D), while CSCs 
nuclei are shown in green (E&F). The mouse endothelial marker Isolectin B4 is showed in 
white in (C) and in magenta in (E), while the endothelial marker human CD34 is showed in 
green in (D) and in red in (F). α-Sarcomeric Actin, that labels cardiomyocyte cytoplasm, is 
depicted in white in (D) and in magenta in (F). Nuclei (DAPI) are identified in blue 
fluorescence. 
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Online figure V. Staining of the human heart with the anti-human nuclei antibody. 
Positive control to verify the labelling efficiency of the antibody used for identification of 
human donor cells in mouse hearts. The labelling efficiency was of 96% (red fluorescence). 
Nuclei (DAPI) are identified in blue fluorescence. Magnification: 400X. 
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Online Figure VI: Validation of immunolabeling by spectral analysis of human-nuclei 
positivity in the mice hearts. 8µm sections of SVP- and CSC-transplanted hearts were 
stained with a mouse anti-Human Nuclei antibody followed by AlexaFluor 568 goat anti-
mouse secondary antibody. (A) Representative confocal single channel Lambda-scan 
acquisition. Samples were excited at a wavelength of 513 nm and the fluorescence emitted 
from the tissue was recorded over the interval from 515 to 750 nm. A series of 30 images 
was acquired. The fluorescence recorded at the different wavelengths is shown in white. 
This operation was followed by both the calculation of the emission spectra and by the 
spectral dye separation. (B) Representative pictures in which the specific Dye emission (in 
red, corresponding to Human Nuclei) was separated from the unspecific emission (in blue) 
performing a spectral dye separation. Unspecific emission is attributable to the presence of 
lipofuscines (in yellow in Suppl. Fig 4D&F). (C) Graphs illustrate that the specific emission 
spectra of the AlexaFluor 568 Dye (on the left, red curves) are clearly distinct from the 
unspecific emission spectra of lipofuscines (on the right, blue curves), and from the 
background autofluorescence of the tissue, showed with black curves, thus confirming the 
accuracy of the analysis indicating the presence of human cells in the recipient hearts. The 
green bar corresponds to the excitation wavelength. A minimum of n=15 emission spectra 
have been reported in each case, randomly collected from CSC- and SVP-injected hearts. 
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Online figure VII. Evaluation of infarct size in mice 42 days post-MI and cell therapy. 
Representative images of Azan Mallory staining in ventricular sections; collagen fibres are 
stained in blue (12.5X magnification). The bar graphs summarize quantitative data of the 
percentage of the LV area occupied by the scar. Data are presented as mean±SEM (n=5-7 
mice per group). 
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Online figure VIII. Separation of the left ventricle (LV) in mice hearts 14 days post-MI. 
For a selected number of mice (n=6 per each MI-group and n=3 Sham) the LV was 
separated from the rest of the heart for histological morphometric evaluation. After the initial 
removal of the atria from the ventricles (A), the right ventricle (RV) was further separated 
from the LV (B&C). 
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Online figure IX. In vitro matrigel assay with SVPs, CSCs and SVPs+CSCs. 
Representative phase-contrast optical images of SVPs, CSCs and SVPs+CSCs forming 
tubular networks when cultured for 5 hrs on Matrigel substrate. Magnification: 100X. 
Histograms summarize quantitative data of the tube length per field. Data are represented 
as mean±SEM. n=4 per each group. * p<0.05 vs. SVPs, §§ p<0.01 vs CSCs.  
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